bc-ontologyGovernments, institutions, geography and law
Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.

21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.

21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses., “Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and…”, is a CFR section of 21 CFR Part 312, Subpart E—Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses; in force.

https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb
schema:Legislation
Download TurtleJSON-LDN-TriplesMarkdown
Cite this
21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb

Elsewhere

Facts

adms:identifier
eli:cites
prov:wasDerivedFrom
schema:isPartOf
schema:legislationIdentifier
21 CFR 312.84
schema:legislationJurisdiction
schema:legislationLegalForce
schema:legislationType
schema:name
Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnessesen
schema:url
skos:prefLabel
21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.en

Related

Cited by (1)eli:cites